CD19 and diffuse large B-cell lymphoma: Autologous CAR-T cell therapy targeting CD19 has shown striking responses, leading to FDA’s approval for the management of precursor B-cell ALL and diffuse large B-cell lymphoma (DLBCL) (Grupp et al., 2013).